Gilead quarterly revenue rises 17% on remdesivir sales

Gilead Sciences Inc reported a 17% rise in quarterly revenue on Wednesday, helped by sales of its antiviral drug remdesivir, the first and only treatment approved in the United States for patients hospitalized with COVID-19.


Reuters | Updated: 29-10-2020 02:56 IST | Created: 29-10-2020 02:01 IST
Gilead quarterly revenue rises 17% on remdesivir sales
Representative image Image Credit: ANI

Gilead Sciences Inc reported a 17% rise in quarterly revenue on Wednesday, helped by sales of its antiviral drug remdesivir, the first and only treatment approved in the United States for patients hospitalized with COVID-19. Remdesivir brought in $873 million in the third quarter, below analysts' estimates of $960 million, according to Refinitiv IBES data.

Shares of Gilead were up 0.5% in extended trading after earlier rising about 2% after the bell. For the full year, Gilead lowered the top end of its sales outlook, saying it now expects 2020 sales of $23 billion to $23.5 billion, compared with its previous forecast of $23 billion to $25 billion.

Third-quarter revenue totaled $6.6 billion, beating the average analyst estimate of $6.31 billion. The company posted adjusted earnings per share of $2.11, topping Wall Street's estimate of $1.90 per share. Remdesivir, sold under the brand name Veklury, was granted emergency use authorization by the U.S. Food and Drug Administration in May after it was shown to shorten hospital stays for COVID-19 patients.

Commercial sales began in July and the FDA formally approved the drug this month, despite recent results from a World Health Organization-sponsored trial showing remdesivir did not improve patient outcomes.

 

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)

Give Feedback